SLC5A2 and diabetes mellitus: Given the presence of SGLT2 in the central nervous system, current evidence suggests that SGLT2 inhibitors, in addition to having other beneficial metabolic effects and reducing cardiovascular risk in heart failure patients regardless of diabetes mellitus status, may also have neuroprotective properties [72].